BioAge Labs (BIOA) Abandons Obesity Drug Amid Shareholder Lawsuit - Hagens Berman
San Francisco, California--(Newsfile Corp. - February 20, 2025) - BioAge Labs, Inc. (NASDAQ: BIOA) is abandoning development of its lead obesity candidate, azelaprag, just weeks after halting a Phase 2 trial. The biotech firm is pivoting to a preclinical neuroinflammation program, according to a recent company disclosure. This decision follows a securities class action lawsuit alleging BioAge made misleading statements and omissions related to its September 2024 initial public offering. The...
2025-02-20 3:36 PM EST
AZN FINAL DEADLINE ALERT: AstraZeneca (AZN) Investors with Losses Encouraged to Contact Hagens Berman Before Feb. 21, 2025 Deadline in Securities Class Action
San Francisco, California--(Newsfile Corp. - February 20, 2025) - AstraZeneca (NASDAQ: AZN), the Anglo-Swedish pharmaceutical giant, has seen its stock price tumble 15 percent over the past six months, buffeted by a series of unsettling reports emanating from China. A widening investigation by China regulators into alleged illegal drug imports, data breaches, and potential health insurance fraud has cast a shadow over the company's prospects in a critical market, triggering a securities class...
2025-02-20 3:24 PM EST
FMC Corporation (FMC) Accused of Misleading Investors About Sales and Inventory - Hagens Berman
San Francisco, California--(Newsfile Corp. - February 18, 2025) - FMC Corporation (NYSE: FMC) a global agricultural sciences company, is facing a class action lawsuit alleging that it misled investors about its business prospects, leading to a significant drop in the company's stock price. The suit, captioned Mohammed v. FMC Corporation, No. 25-cv-00771 (E.D. Pa.), accuses FMC and certain of its current and former executives of violating the Securities Exchange Act of 193. Hagens Berman is...
2025-02-18 8:35 AM EST
Novo Nordisk (NVO) Faces Securities Class Action After Weight Loss Therapy Trial Data Disappoints, Analyst Questions Trial's Design - Hagens Berman
San Francisco, California--(Newsfile Corp. - February 13, 2025) - Novo Nordisk A/S (NYSE: NVO) is facing a class-action lawsuit from investors who allege the pharmaceutical giant misled them about the prospects of its experimental obesity drug, CagriSema. Hagens Berman urges investors who purchased Novo Nordisk shares and suffered substantial losses to submit your losses now. The firm also encourages persons with knowledge of the trial and its design to contact the firm's attorneys. Class...
2025-02-13 2:00 PM EST
Crocs, Inc. (CROX) Faces Securities Class Action over HEYDUDE Pipeline - Hagens Berman
San Francisco, California--(Newsfile Corp. - February 13, 2025) - Investors in Crocs, Inc. (NASDAQ: CROX) suffered yet another loss on Oct. 29, 2024 after the company prepared investors for disappointing Q4 and FY 2024 financial results that, in turn, sent shares crashing $26.47 (-19%). According to the company, the culprit was its HEYDUDE operating segment performance. Now a class action lawsuit has been filed focused on the propriety of Crocs' disclosures about sales practices within its...
2025-02-13 1:55 PM EST
Block, Inc. (XYZ) Faces Securities Class Action, Regulators Levy Cash App Fines Following Investigations Going Back to Hindenburg Report- Hagens Berman
San Francisco, California--(Newsfile Corp. - February 13, 2025) - Investors in Block, Inc. (NYSE: SQ) n/k/a (NYSE: XYZ) began to learn of potentially adverse information about the company and its Square and Cash App platforms on Mar. 23, 2023, when Hindenburg Research published a scathing report on the company. After a 2-year investigation, which included dozens of interviews with former employees, partners, and industry experts, Hindenburg concluded, in part, that Block had "wildly...
2025-02-13 1:52 PM EST
Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report- Hagens Berman
San Francisco, California--(Newsfile Corp. - February 13, 2025) - Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is facing mounting pressure on multiple fronts. Following disappointing sales figures and ongoing legal challenges, analysts TD Cowen recently lowered its price target for Regeneron to $1,030 from $1,230. The downward revision reflects preannounced January figures for EYLEA®, a key product in Regeneron's portfolio, with TD Cowen citing increased competition in the market and...
2025-02-13 1:49 PM EST
BioAge Labs (BIOA) Shares Plummet After Discontinuing Trial Just 2 Months After IPO- Hagens Berman
San Francisco, California--(Newsfile Corp. - February 13, 2025) - BioAge Labs (NASDAQ: BIOA), a biopharmaceutical company focused on metabolic diseases, is facing a class-action lawsuit from shareholders who allege the company misled investors about the safety and prospects of a key drug candidate before its initial public offering last September. Hagens Berman urges investors who purchased BioAge shares in the company's IPO or on the open market and suffered substantial losses to submit your...
2025-02-13 1:42 PM EST
FTAI Aviation Ltd. (FTAI) Faces Intensified Scrutiny Following Second Short-Seller Report Amid Investor Class Action - Hagens Berman
San Francisco, California--(Newsfile Corp. - February 13, 2025) - FTAI Aviation Ltd. (NASDAQ: FTAI) is facing mounting pressure after a second activist short-seller, Snowcap, released a critical report on January 29, 2025, further amplifying concerns initially raised by Muddy Waters Research earlier in January and leading to an investor class action alleging securities fraud. Hagens Berman urges FTAI Aviation investors to submit your losses now. Class Period: July 23, 2024 - Jan. 15, 2025...
2025-02-13 1:37 PM EST
AstraZeneca (AZN) Faces Securities Class Action After Reports of PRC Probe into Fraud and Corruption - Hagens Berman
San Francisco, California--(Newsfile Corp. - February 13, 2025) - AstraZeneca (NASDAQ: AZN), the Anglo-Swedish pharmaceutical giant, has seen its stock price tumble 15 percent over the past six months, buffeted by a series of unsettling reports emanating from China. A widening investigation by China regulators into alleged illegal drug imports, data breaches, and potential health insurance fraud has cast a shadow over the company's prospects in a critical market, triggering a securities class...
2025-02-13 1:26 PM EST
Cardlytics (CDLX) Faces Investor Lawsuit Over Growth Projections - Hagens Berman
San Francisco, California--(Newsfile Corp. - February 13, 2025) - Cardlytics, the advertising technology company that connects marketers with consumers through their banking apps, is facing a class-action lawsuit alleging that it misled investors about its growth prospects. Hagens Berman urges Cardlytics, Inc. (NASDAQ: CDLX) investors who suffered substantial losses to submit your losses now. The firm also encourages persons with knowledge who may be able to assist in the investigation to...
2025-02-13 1:18 PM EST
Block, Inc. (XYZ) Faces Securities Class Action, Regulators Levy Cash App Fines Following Investigations Going Back to Hindenburg Report- Hagens Berman
San Francisco, California--(Newsfile Corp. - February 6, 2025) - Investors in Block, Inc. (NYSE: SQ) n/k/a (NYSE: XYZ) began to learn of potentially adverse information about the company and its Square and Cash App platforms on Mar. 23, 2023, when Hindenburg Research published a scathing report on the company. After a 2-year investigation, which included dozens of interviews with former employees, partners, and industry experts, Hindenburg concluded, in part, that Block had "wildly overstated...
2025-02-06 4:02 PM EST
Analyst Cuts Regeneron Pharmaceuticals (REGN) Price Target After Sales Concerns and Investor Lawsuit- Hagens Berman
San Francisco, California--(Newsfile Corp. - February 6, 2025) - Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is facing mounting pressure on multiple fronts. Following disappointing sales figures and ongoing legal challenges, analysts TD Cowen recently lowered its price target for Regeneron to $1,030 from $1,230. The downward revision reflects preannounced January figures for EYLEA®, a key product in Regeneron's portfolio, with TD Cowen citing increased competition in the market and...
2025-02-06 4:00 PM EST
BioAge Labs (BIOA) Faces Securities Class Action On Behalf Of IPO Investors After Discontinuing Weight-Loss Drug Trial- Hagens Berman
San Francisco, California--(Newsfile Corp. - February 6, 2025) - BioAge Labs (NASDAQ: BIOA), a biopharmaceutical company focused on metabolic diseases, is facing a class-action lawsuit from shareholders who allege the company misled investors about the safety and prospects of a key drug candidate before its initial public offering last September. Hagens Berman urges investors who purchased BioAge shares in the company's IPO or on the open market and suffered substantial losses to submit your...
2025-02-06 3:44 PM EST
Crocs, Inc. (CROX) Faces Securities Class Action over HEYDUDE Pipeline - Hagens Berman
San Francisco, California--(Newsfile Corp. - February 6, 2025) - Investors in Crocs, Inc. (NASDAQ: CROX) suffered yet another loss on Oct. 29, 2024 after the company prepared investors for disappointing Q4 and FY 2024 financial results that, in turn, sent shares crashing $26.47 (-19%). According to the company, the culprit was its HEYDUDE operating segment performance. Now a class action lawsuit has been filed focused on the propriety of Crocs' disclosures about sales practices within its...
2025-02-06 3:01 PM EST
Novo Nordisk (NVO) Faces Securities Class Action After Weight Loss Therapy Trial Data Disappoints, Analyst Questions Trial's Design - Hagens Berman
San Francisco, California--(Newsfile Corp. - February 6, 2025) - Novo Nordisk A/S (NYSE: NVO) is facing a class-action lawsuit from investors who allege the pharmaceutical giant misled them about the prospects of its experimental obesity drug, CagriSema. Hagens Berman urges investors who purchased Novo Nordisk shares and suffered substantial losses to submit your losses now. The firm also encourages persons with knowledge of the trial and its design to contact the firm's attorneys. Class...
2025-02-06 2:57 PM EST
Cardlytics (CDLX) Faces Investor Lawsuit Over Growth Projections - Hagens Berman
San Francisco, California--(Newsfile Corp. - February 6, 2025) - Cardlytics, the advertising technology company that connects marketers with consumers through their banking apps, is facing a class-action lawsuit alleging that it misled investors about its growth prospects. Hagens Berman urges Cardlytics, Inc. (NASDAQ: CDLX) investors who suffered substantial losses to submit your losses now. The firm also encourages persons with knowledge who may be able to assist in the investigation to...
2025-02-06 2:45 PM EST
FTAI Aviation Ltd. (FTAI) Faces Intensified Scrutiny Following Second Short-Seller Report Amid Investor Class Action - Hagens Berman
San Francisco, California--(Newsfile Corp. - February 4, 2025) - FTAI Aviation Ltd. (NASDAQ: FTAI) is facing mounting pressure after a second activist short-seller, Snowcap, released a critical report on January 29, 2025, further amplifying concerns initially raised by Muddy Waters Research earlier in January and leading to an investor class action alleging securities fraud. Hagens Berman urges FTAI Aviation investors to submit your losses now. Class Period: July 23, 2024 - Jan. 15, 2025 Lead...
2025-02-04 3:56 PM EST
SYM FINAL DEADLINE ALERT: Symbotic (SYM) Investors with Losses Encouraged to Contact Hagens Berman Before Feb. 3rd, 2025 Deadline in Securities Class Action
San Francisco, California--(Newsfile Corp. - February 2, 2025) - Symbotic Inc. (NASDAQ: SYM), a Wilmington, Mass.-based automation technology company, has filed restated financial statements for three fiscal 2024 quarters, revealing significant errors in its previously reported revenue and profitability figures. The restatements, filed on December 4, follow the revelation of accounting errors last month and come as the company faces a securities fraud class action lawsuit. Hagens Berman has...
2025-02-02 12:05 PM EST
Novo Nordisk (NVO) Faces Securities Class Action After Weight Loss Therapy Trial Data Disappoints, Analyst Questions Trial's Design - Hagens Berman
San Francisco, California--(Newsfile Corp. - January 31, 2025) - Novo Nordisk A/S (NYSE: NVO) is facing a class-action lawsuit from investors who allege the pharmaceutical giant misled them about the prospects of its experimental obesity drug, CagriSema. Hagens Berman urges investors who purchased Novo Nordisk shares and suffered substantial losses to submit your losses now. The firm also encourages persons with knowledge of the trial and its design to contact the firm's attorneys. Class...
2025-01-31 8:32 AM EST